Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.

American journal of hematology - 1 Dec 2004

Takao Toshitatsu, Kobayashi Yutaka, Kuroda Junya, Omoto Atsusi, Nishimura Tomoko, Kamitsuji Yuri, Fukiya Etsuko, Nakamura Chie, Kimura Shinya, Yoshikawa Toshikazu

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20
Share to Ascitic Fluid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 8, Human

Share to Lymphoma, B-Cell

Share to Pleural Effusion

Share to Remission Induction

Share to Rituximab

Source

Identifiers

PMID: 15551361
DOI: 10.1002/ajh.20227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.PMID 15551361Read ↗

Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.Semantic proximity Read ↗

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.Semantic proximity Read ↗

Hepatitis C Virus-Associated Non-Hodgkin Lymphomas: Biology, Epidemiology, and Treatment.Semantic proximity Read ↗

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.Semantic proximity Read ↗

Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.Semantic proximity Read ↗

Do hepatitis C Virus genotypes influence liver dysfunction following rituximab-containing regimens in patients with diffuse large B cell lymphoma?Semantic proximity Read ↗

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.Semantic proximity Read ↗

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.Semantic proximity Read ↗

Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.Semantic proximity Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.